Histopathologic Validation of 3′-Deoxy-3′-18F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity

被引:18
作者
Troost, Esther G. C. [1 ]
Bussink, Johan [1 ]
Slootweg, Piet J. [2 ]
Peeters, Wenny J. M. [1 ]
Merkx, Matthias A. W. [3 ]
van der Kogel, Albert J. [1 ]
Oyen, Wim J. G. [4 ]
Kaanders, Johannes H. A. M. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Maxillofacial Surg, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands
关键词
F-18-fluorothymidine PET; proliferation; head and neck cancer; immunohistochemistry; iododeoxyuridine; thymidine kinase; CYTOSOLIC THYMIDINE KINASE; F-18-FLT PET; NECK-CANCER; IMAGING PROLIFERATION; NUCLEAR ANTIGEN; IN-VIVO; RADIOTHERAPY; HEAD; REPOPULATION; THERAPY;
D O I
10.2967/jnumed.109.071910
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Accelerated tumor cell repopulation is an important mechanism adversely affecting therapeutic outcome in head and neck cancer. The noninvasive assessment of the proliferative state of a tumor by PET may provide a selection tool for customized treatment. 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) is a PET tracer that is phosphorylated by thymidine kinase 1 (TK-1) and, as such, reflects cellular proliferation. Before the use of F-18-FLT PET for tumor characterization is accepted and introduced into clinical studies, validation against tumor histology is mandatory. The aim of this study was to validate F-18-FLT PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the proliferation marker iododeoxyuridine and for TK-1. Methods: Seventeen patients with primary squamous cell carcinomas of the oral cavity underwent an F-18-FLT PET/CT scan before surgery, and iododeoxyuridine was administered 20 min before tumor resection. F-18-FLT PET/CT scans were segmented, and PET/CT volumes and PET signal intensities were calculated (mean standardized uptake value [SUVmean] and maximum standardized uptake value [SUVmax]). Multiple paraffin-embedded tumor sections were immunohistochemically stained for iododeoxyuridine and TK-1. For iododeoxyuridine, labeling indices and optical densities were calculated and correlated with SUVmean and SUVmax. TK-1 staining was visually and semiquantitatively assessed. Results: All primary tumors were identified with F-18-FLT PET but with a large range in tracer uptake (mean SUVmax, 5.9; range, 2.2-15.2). Also, there was a large variability in iododeoxyuridine labeling indices (mean, 0.09; range, 0.01-0.29) and optical densities (mean, 28.2; range, 12.6-37.8). The iododeoxyuridine optical densities correlated significantly with SUVmean and SUVmax, but the labeling indices did not. In most tumors, TK-1 staining of varying intensity was present but correlated with neither iododeoxyuridine binding nor F-18-FLT uptake. Conclusion: The current study demonstrated only a weak correlation between F-18-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. This weak correlation may be explained by differences in biomarker characteristics, resolution, and quantification methods.
引用
收藏
页码:713 / 719
页数:7
相关论文
共 50 条
  • [31] Comparison of characteristics of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET during staging of esophageal squamous cell carcinoma
    Ma, Changsheng
    Li, Dengwang
    Yin, Yong
    Cao, Jianping
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (12) : 1181 - 1186
  • [32] 3′-DEOXY-3′-[18F]FLUOROTHYMIDINE PET QUANTIFICATION OF BONE MARROW RESPONSE TO RADIATION DOSE
    McGuire, Sarah M.
    Menda, Yusuf
    Ponto, Laura L. Boles
    Gross, Brandie
    Buatti, John
    Bayouth, John E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03): : 888 - 893
  • [33] Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography
    de Langen, Adrianus J.
    Klabbers, Bianca
    Lubberink, Mark
    Boellaard, Ronald
    Spreeuwenberg, Marieke D.
    Slotman, Ben J.
    de Bree, Remco
    Smit, Egbert F.
    Hoekstra, Otto S.
    Lammertsma, Adriaan A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (03) : 389 - 395
  • [34] Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-18F-Fluorothymidine PET and Diffusion-Weighted MR Imaging
    Schelhaas, Sonja
    Wachsmuth, Lydia
    Viel, Thomas
    Honess, Davina J.
    Heinzmann, Kathrin
    Smith, Donna-Michelle
    Hermann, Sven
    Wagner, Stefan
    Kuhlmann, Michael T.
    Mueller-Tidow, Carsten
    Kopka, Klaus
    Schober, Otmar
    Schaefers, Michael
    Schneider, Richard
    Aboagye, Eric O.
    Griffiths, John
    Faber, Cornelius
    Jacobs, Andreas H.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (06) : 983 - 988
  • [35] A facile and rapid automated synthesis of 3′-deoxy-3′-[18F]fluorothymidine
    Tang, Ganghua
    Tang, Xiaolan
    Wen, Fuhua
    Wang, Mingfang
    Li, Baoyuan
    [J]. APPLIED RADIATION AND ISOTOPES, 2010, 68 (09) : 1734 - 1739
  • [36] A simplified analysis of [18F]3′-deoxy-3′-fluorothymidine metabolism and retention
    Anthony F. Shields
    David A. Briston
    Samatha Chandupatla
    Kirk A. Douglas
    Jawana Lawhorn-Crews
    Jerry M. Collins
    Thomas J. Mangner
    Lance K. Heilbrun
    Otto Muzik
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32 : 1269 - 1275
  • [37] A simplified analysis of [18F]3'-deoxy-3′-fluorothymidine metabolism and retention
    Shields, AF
    Briston, DA
    Chandupatla, S
    Douglas, KA
    Lawhorn-Crews, J
    Collins, JM
    Mangner, TJ
    Heilbrun, LK
    Muzik, O
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (11) : 1269 - 1275
  • [38] Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine:: [18F]FLT for imaging of cellular proliferation in vivo
    Grierson, JR
    Shields, AF
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2000, 27 (02) : 143 - 156
  • [39] A Phase II Study of 3′-Deoxy-3′-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688
    Kostakoglu, Lale
    Duan, Fenghai
    Idowu, Michael O.
    Jolles, Paul R.
    Bear, Harry D.
    Muzi, Mark
    Cormack, Jean
    Muzi, John P.
    Pryma, Daniel A.
    Specht, Jennifer M.
    Hovanessian-Larsen, Linda
    Miliziano, John
    Mallett, Sharon
    Shields, Anthony F.
    Mankoff, David A.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) : 1681 - 1689
  • [40] Preclinical Evidence That 3′-Deoxy-3′-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy
    Schelhaas, Sonja
    Held, Annelena
    Baeumer, Nicole
    Viel, Thomas
    Hermann, Sven
    Mueller-Tidow, Carsten
    Jacobs, Andreas H.
    [J]. CANCER RESEARCH, 2016, 76 (24) : 7089 - 7095